Cracked Gaskets and Rust-Like Residues Trigger FDA Warning Letter to Alchymars

Why It Matters

The letter highlights persistent quality‑system gaps that could jeopardize the supply of critical drug ingredients to the U.S. market and trigger further regulatory penalties for non‑compliant suppliers.

Key Takeaways

• FDA issued second warning to Alchymars for equipment disrepair.
• Cracked gaskets and rust residues found on API production lines.
• Company’s corrective plan lacked residue testing and lifecycle management.
• Prior 2018 warning led to 2023 closeout, now re‑issued.
• Non‑payment of GDUFA fees may restrict Alchymars in FDA filings.

Pulse Analysis

The FDA’s latest warning to Alchymars underscores a broader shift toward tighter enforcement of Good Manufacturing Practices at overseas API facilities. Inspectors focus on tangible signs of equipment degradation—cracked gaskets, rust‑like deposits, and wet paint—because such conditions directly increase the risk of cross‑contamination and product impurity. By demanding documented lifecycle‑management programs and residue testing, regulators aim to close gaps that have historically led to costly recalls and market withdrawals.

Alchymars’ case is emblematic of a recurring compliance challenge. After a 2018 warning highlighted deteriorating gaskets and unsanitary washrooms, the company secured a 2023 closeout by addressing those specific issues. However, the recent letter reveals that superficial fixes without robust quality‑system upgrades are insufficient. The firm’s admission of inadequate record‑keeping and the absence of a systematic inspection regimen raise concerns for generic drug manufacturers that rely on its APIs, potentially prompting them to diversify suppliers or renegotiate contracts to mitigate supply‑chain risk.

The enforcement wave extends beyond Alchymars, with GC America and Sato Pharmaceutical also cited for lapses in component testing and aseptic filling environments. Coupled with the reminder that Alchymars is delinquent on its Generic Drug User Fee Amendments (GDUFA) payments—an issue that can bar a facility from being listed in certain FDA submissions—the episode signals heightened financial and operational stakes for foreign suppliers. Companies seeking to maintain U.S. market access must invest in comprehensive equipment maintenance programs, rigorous testing protocols, and timely fee compliance to avoid regulatory setbacks and preserve their competitive edge.